To the Editor Sun et al1 conducted a cost-effectiveness analysis of multigene testing among women with breast cancer. The authors state that multiple genetic tests have the potential to reveal more variation (formerly mutation) carriers when an unselected population of patients with breast cancer are targeted and could be more cost-effective in UK and US health systems compared with current family history–based population screenings. This research highlights the importance of screening of an unselected population with breast cancer, which could have an immediate translational influence on patient outcomes. We offer a few suggestions that could help to further strengthen the approach.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jun I, Berger AL, Yaghjyan L. Future Research Suggestions for Multigene Testing in Unselected Populations. JAMA Oncol. 2020;6(5):785. doi:10.1001/jamaoncol.2020.0128
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: